ABT
NEUTRAL
$101.56
Live
Abbott Laboratories · NYSE
Target $131.44
(+29.4%)
$99.05
52W Range
$139.06
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 16, 2026
Market cap
$176.48B
P/E
27.3
ROE
13.0%
Profit margin
14.7%
Debt/Equity
0.27
Dividend yield
2.49%
AI Analysis
AI-powered fundamental assessment
Confidence
85%
Abbott Laboratories exhibits strong fundamental health with a Piotroski F-Score of 7/9 and a very conservative debt-to-equity ratio of 0.27. However, the stock is currently in a severe technical downtrend (0/100) and trades at a significant premium to its Graham Number ($50.12) and Intrinsic Value ($26.04). While analyst targets suggest significant upside to $131.44, the combination of bearish insider selling and poor short-term price performance offsets the strong balance sheet.
Key Strengths
Strong financial health indicated by a Piotroski F-Score of 7/9
Very low leverage with a Debt/Equity ratio of 0.27
Impressive historical earnings track record with consistent beats over 25 quarters
High gross margins (56.66%) and healthy operating margins (21.62%)
Strong analyst support with a mean target price of $131.44
Key Risks
Severe technical bearishness with a 0/100 trend score and -21.1% 6-month return
Significant valuation gap between current price ($101.56) and Graham Number ($50.12)
Bearish insider sentiment with multiple officer sales and zero buys
Stagnant revenue growth (4.40% YoY) relative to the healthcare sector average
Extreme volatility in YoY earnings growth (-80.90%)
AI Fair Value Estimate
Based on comprehensive analysis
$88.5
-12.9% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
55
Moderate
30
50
40
90
65
AI Verdict
Fundamentally sound but technically broken and overvalued.
Key drivers: Piotroski F-Score, Technical Trend, Graham Number, Debt/Equity
Confidence
90%
Value
30/100
P/E of 27.30 and Graham Number of $50.12 suggest the stock is trading at a high quality premium.
Positives
- Forward P/E (16.63) is lower than current P/E
Watchpoints
- Price is >100% above Graham Number
- Price is >280% above growth-based intrinsic value
Future
50/100
Growth metrics are mixed; long-term stability is high but immediate growth is sluggish.
Positives
- Consistent EPS beat history
- Positive Q/Q EPS growth (+15.4%)
Watchpoints
- Low YoY revenue growth (4.4%)
- Negative YoY earnings growth (-80.9%)
Past
40/100
Recent price performance is heavily bearish despite historical stability.
Positives
- Long-term earnings consistency
Watchpoints
- 1Y Change: -18.4%
- 6M Change: -21.1%
Health
90/100
Balance sheet is exceptionally strong and low-risk.
Positives
- Piotroski F-Score 7/9
- Low Debt/Equity (0.27)
- Current Ratio 1.58
Watchpoints
- Altman Z-Score not provided
Dividend
65/100
Dividend is sustainable but not a primary driver for total return.
Positives
- Consistent dividend rate of $2.52
Watchpoints
- Payout ratio (63.44%) is moderately high
- Yield (2.49%) is average for the sector
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$101.56
Analyst Target
$131.44
Upside/Downside
+29.4%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ABT and closest competitors.
Updated 2026-04-15
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ABT
Abbott Laboratories
Primary
|
-10.8% | +2.5% | -18.4% | -21.1% | -7.6% | -1.9% |
|
GILD
Gilead Sciences, Inc.
Peer
|
+152.7% | +86.0% | +27.7% | +27.1% | -6.6% | +0.9% |
|
TMO
Thermo Fisher Scientific Inc.
Peer
|
+10.2% | -12.2% | +3.1% | -6.4% | -2.4% | +1.1% |
|
ISRG
Intuitive Surgical, Inc.
Peer
|
+85.0% | +80.5% | -6.9% | +3.1% | -7.1% | -2.3% |
|
AMGN
Amgen Inc.
Peer
|
+65.2% | +59.9% | +16.5% | +26.4% | -8.8% | +1.0% |
ABT
Abbott Laboratories
Primary
5Y
-10.8%
3Y
+2.5%
1Y
-18.4%
6M
-21.1%
1M
-7.6%
1W
-1.9%
GIL
Gilead Sciences, Inc.
Peer
5Y
+152.7%
3Y
+86.0%
1Y
+27.7%
6M
+27.1%
1M
-6.6%
1W
+0.9%
TMO
Thermo Fisher Scientific Inc.
Peer
5Y
+10.2%
3Y
-12.2%
1Y
+3.1%
6M
-6.4%
1M
-2.4%
1W
+1.1%
ISR
Intuitive Surgical, Inc.
Peer
5Y
+85.0%
3Y
+80.5%
1Y
-6.9%
6M
+3.1%
1M
-7.1%
1W
-2.3%
AMG
Amgen Inc.
Peer
5Y
+65.2%
3Y
+59.9%
1Y
+16.5%
6M
+26.4%
1M
-8.8%
1W
+1.0%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
27.3
Forward P/E
16.63
PEG Ratio
1.46
P/B Ratio
3.38
P/S Ratio
3.98
EV/Revenue
4.11
EV/EBITDA
15.15
Market Cap
$176.48B
Profitability
Profit margins and return metrics
Profit Margin
14.72%
Operating Margin
21.62%
Gross Margin
56.66%
ROE
12.96%
ROA
6.63%
Growth
Revenue and earnings growth rates
Revenue Growth
+4.4%
Earnings Growth
-80.9%
Q/Q Revenue Growth
+4.42%
Q/Q Earnings Growth
-80.8%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.27
Low debt
Current Ratio
1.58
Good
Quick Ratio
1.02
Good
Cash/Share
$5.14
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$11.5B
Gross Margin
57.0%
Op. Margin
19.6%
Net Margin
15.5%
Total Assets
$86.7B
Liabilities
$33.9B
Equity
$52.1B
Debt/Equity
0.65x
Operating CF
$3.3B
CapEx
$-0.7B
Free Cash Flow
$2.6B
FCF Yield
79%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-04-16
$N/A
2026-01-22
$1.5
+0.3% surprise
2025-10-15
$1.3
+0.1% surprise
2025-07-17
$1.01
+1.9% surprise
Healthcare Sector Comparison
Comparing ABT against 393 companies in the Healthcare sector
(24 bullish, 129 neutral, 240 bearish)
P/E Ratio
27.3
This Stock
vs
90.61
Sector Avg
-69.9%
(Discount)
Return on Equity (ROE)
12.96%
This Stock
vs
-101.52%
Sector Avg
-112.8%
(Below Avg)
Profit Margin
14.72%
This Stock
vs
-12.47%
Sector Avg
-218.0%
(Weaker)
Debt to Equity
0.27
This Stock
vs
3.4
Sector Avg
-92.1%
(Less Debt)
Revenue Growth
4.4%
This Stock
vs
124.21%
Sector Avg
-96.5%
(Slower)
Current Ratio
1.58
This Stock
vs
4.56
Sector Avg
-65.4%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ABT
Abbott Laboratories
|
NEUTRAL | $176.48B | 27.3 | 13.0% | 14.7% | $101.56 | |
|
GILD
Gilead Sciences, Inc.
|
BULLISH | $172.99B | 21.02 | 40.7% | 28.9% | $139.37 | Compare |
|
TMO
Thermo Fisher Scientific Inc.
|
NEUTRAL | $184.28B | 27.96 | 13.0% | 15.0% | $496.06 | Compare |
|
ISRG
Intuitive Surgical, Inc.
|
NEUTRAL | $163.73B | 58.5 | 16.7% | 28.4% | $460.99 | Compare |
|
AMGN
Amgen Inc.
|
NEUTRAL | $189.67B | 24.71 | 106.1% | 21.0% | $351.85 | Compare |
ABT
Abbott Laboratories
NEUTRAL
Mkt Cap
$176.5B
P/E
27.3
ROE
13.0%
Price
$101.56
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-23 | ORVILLE JACOB A | Officer | Stock Award | 13,255 | - |
| 2026-03-02 | MORELAND MARY K | Officer | Sale | 613 | $70,851 |
| 2026-03-02 | MORRONE LOUIS H | Officer | Sale | 1,144 | $132,224 |
| 2026-03-02 | SHROFF ERIC | Officer | Sale | 709 | $81,946 |
| 2026-03-02 | CUSHMAN ELIZABETH C | General Counsel | Sale | 263 | $30,398 |
| 2026-03-02 | SALVADORI DANIEL GESUA SIVE | Officer | Sale | 885 | $102,288 |
| 2026-03-02 | MCCOY JOHN A. JR | Officer | Sale | 585 | $67,614 |
| 2026-02-24 | SCOGGINS CHRISTOPHER J | Officer | Stock Award | 18,502 | - |
| 2026-02-24 | MORELAND MARY K | Officer | Stock Award | 13,951 | - |
| 2026-02-24 | BOUDREAU PHILIP P | Chief Financial Officer | Stock Award | 27,997 | - |
| 2026-02-24 | MORRONE LOUIS H | Officer | Stock Award | 15,418 | - |
| 2026-02-24 | SHROFF ERIC | Officer | Stock Award | 10,873 | - |
| 2026-02-24 | CUSHMAN ELIZABETH C | General Counsel | Stock Award | 15,031 | - |
| 2026-02-24 | SALVADORI DANIEL GESUA SIVE | Officer | Stock Award | 21,644 | - |
| 2026-02-24 | MCCOY JOHN A. JR | Officer | Stock Award | 5,373 | - |
ORVILLE JACOB A
Officer
2026-03-23
13,255 shares
MORELAND MARY K
Officer
2026-03-02
613 shares
·
$70,851
MORRONE LOUIS H
Officer
2026-03-02
1,144 shares
·
$132,224
SHROFF ERIC
Officer
2026-03-02
709 shares
·
$81,946
CUSHMAN ELIZABETH C
General Counsel
2026-03-02
263 shares
·
$30,398
SALVADORI DANIEL GESUA SIVE
Officer
2026-03-02
885 shares
·
$102,288
MCCOY JOHN A. JR
Officer
2026-03-02
585 shares
·
$67,614
SCOGGINS CHRISTOPHER J
Officer
2026-02-24
18,502 shares
MORELAND MARY K
Officer
2026-02-24
13,951 shares
BOUDREAU PHILIP P
Chief Financial Officer
2026-02-24
27,997 shares
MORRONE LOUIS H
Officer
2026-02-24
15,418 shares
SHROFF ERIC
Officer
2026-02-24
10,873 shares
CUSHMAN ELIZABETH C
General Counsel
2026-02-24
15,031 shares
SALVADORI DANIEL GESUA SIVE
Officer
2026-02-24
21,644 shares
MCCOY JOHN A. JR
Officer
2026-02-24
5,373 shares
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
25 analysts
Goldman Sachs
2026-04-09
Buy
Buy
Barclays
2026-04-08
Overweight
Overweight
Evercore ISI Group
2026-04-06
Outperform
Outperform
BTIG
2026-03-31
Buy
Buy
Citigroup
2026-03-11
Buy
Buy
Barclays
2026-02-02
Overweight
Overweight
Freedom Broker
2026-01-29
Hold
Buy
Citigroup
2026-01-23
Buy
Buy
Bernstein
2026-01-23
Outperform
Outperform
RBC Capital
2026-01-23
Outperform
Outperform
Past News Coverage
Recent headlines mentioning ABT from our newsroom.
Newest → oldest
No matching news yet.